New England Journal of Medicine最新文献

筛选
英文 中文
BCG Revaccination to Prevent Tuberculosis. 重新接种卡介苗预防结核病。
IF 158.5 1区 医学
New England Journal of Medicine Pub Date : 2025-07-24 DOI: 10.1056/nejmc2507859
Manish Joshi,Thaddeus Bartter,Anita Joshi
{"title":"BCG Revaccination to Prevent Tuberculosis.","authors":"Manish Joshi,Thaddeus Bartter,Anita Joshi","doi":"10.1056/nejmc2507859","DOIUrl":"https://doi.org/10.1056/nejmc2507859","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"27 1","pages":"412"},"PeriodicalIF":158.5,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144693370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. Obinutuzumab治疗活动性狼疮性肾炎的疗效和安全性。
IF 96.2 1区 医学
New England Journal of Medicine Pub Date : 2025-07-24 DOI: 10.1056/NEJMc2506672
Grégoire Martin de Frémont, Véronique Le Guern, Nathalie Costedoat-Chalumeau
{"title":"Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.","authors":"Grégoire Martin de Frémont, Véronique Le Guern, Nathalie Costedoat-Chalumeau","doi":"10.1056/NEJMc2506672","DOIUrl":"https://doi.org/10.1056/NEJMc2506672","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"393 4","pages":"409-410"},"PeriodicalIF":96.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a). Reply. Lepodisiran -一种长效小干扰RNA靶向脂蛋白(A)。回复。
IF 96.2 1区 医学
New England Journal of Medicine Pub Date : 2025-07-24 DOI: 10.1056/NEJMc2507989
Steven E Nissen, Ann Marie Navar, John H Krege
{"title":"Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a). Reply.","authors":"Steven E Nissen, Ann Marie Navar, John H Krege","doi":"10.1056/NEJMc2507989","DOIUrl":"https://doi.org/10.1056/NEJMc2507989","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"393 4","pages":"411-412"},"PeriodicalIF":96.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ivermectin against Malaria - Good News in Bad Times. 伊维菌素抗疟疾——艰难时期的好消息。
IF 158.5 1区 医学
New England Journal of Medicine Pub Date : 2025-07-24 DOI: 10.1056/nejme2507797
Richard W Steketee
{"title":"Ivermectin against Malaria - Good News in Bad Times.","authors":"Richard W Steketee","doi":"10.1056/nejme2507797","DOIUrl":"https://doi.org/10.1056/nejme2507797","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"19 1","pages":"402-404"},"PeriodicalIF":158.5,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144693372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Competency-Based Medical Education at the Front Lines of Patient Care. 以能力为本的第一线病人护理医学教育。
IF 158.5 1区 医学
New England Journal of Medicine Pub Date : 2025-07-24 DOI: 10.1056/nejmra2411880
Dawn Cooper,Eric S Holmboe
{"title":"Competency-Based Medical Education at the Front Lines of Patient Care.","authors":"Dawn Cooper,Eric S Holmboe","doi":"10.1056/nejmra2411880","DOIUrl":"https://doi.org/10.1056/nejmra2411880","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"700 1","pages":"376-388"},"PeriodicalIF":158.5,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144693374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enteral Nutrition in Hospitalized Adults. 住院成人肠内营养。
IF 158.5 1区 医学
New England Journal of Medicine Pub Date : 2025-07-24 DOI: 10.1056/nejmc2506662
Thomas E Finucane
{"title":"Enteral Nutrition in Hospitalized Adults.","authors":"Thomas E Finucane","doi":"10.1056/nejmc2506662","DOIUrl":"https://doi.org/10.1056/nejmc2506662","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"121 1","pages":"415"},"PeriodicalIF":158.5,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144693368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. 曲妥珠单抗、德鲁西替康或Ramucirumab联合紫杉醇治疗胃癌。
IF 96.2 1区 医学
New England Journal of Medicine Pub Date : 2025-07-24 Epub Date: 2025-05-31 DOI: 10.1056/NEJMoa2503119
Kohei Shitara, Eric Van Cutsem, Mahmut Gümüş, Sara Lonardi, Christelle de la Fouchardière, Clélia Coutzac, Jeroen Dekervel, Daniel Hochhauser, Lin Shen, Wasat Mansoor, Bo Liu, Lorenzo Fornaro, Min-Hee Ryu, Jeeyun Lee, Cátia Faustino, Jean-Philippe Metges, Josep Tabernero, Fábio Franke, Yelena Y Janjigian, Fabricio Souza, Lori Jukofsky, Yumin Zhao, Takahiro Kamio, Aziz Zaanan, Filippo Pietrantonio
{"title":"Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer.","authors":"Kohei Shitara, Eric Van Cutsem, Mahmut Gümüş, Sara Lonardi, Christelle de la Fouchardière, Clélia Coutzac, Jeroen Dekervel, Daniel Hochhauser, Lin Shen, Wasat Mansoor, Bo Liu, Lorenzo Fornaro, Min-Hee Ryu, Jeeyun Lee, Cátia Faustino, Jean-Philippe Metges, Josep Tabernero, Fábio Franke, Yelena Y Janjigian, Fabricio Souza, Lori Jukofsky, Yumin Zhao, Takahiro Kamio, Aziz Zaanan, Filippo Pietrantonio","doi":"10.1056/NEJMoa2503119","DOIUrl":"10.1056/NEJMoa2503119","url":null,"abstract":"<p><strong>Background: </strong>On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric cancer or gastroesophageal junction adenocarcinoma who had previously received trastuzumab-based therapy. Ramucirumab plus paclitaxel is also a standard second-line treatment option regardless of HER2 status.</p><p><strong>Methods: </strong>We conducted an international, randomized, phase 3 trial comparing second-line trastuzumab deruxtecan at a dose of 6.4 mg per kilogram of body weight with ramucirumab plus paclitaxel in patients with HER2-positive metastatic gastric cancer or gastroesophageal junction adenocarcinoma confirmed on tumor biopsy conducted after the patient had progression while receiving trastuzumab-based therapy. The primary end point was overall survival. Secondary end points included progression-free survival, confirmed objective response (complete or partial response lasting ≥4 weeks), disease control, duration of response, and safety.</p><p><strong>Results: </strong>Among 494 patients who had undergone randomization, overall survival was significantly longer with trastuzumab deruxtecan than with ramucirumab plus paclitaxel (median, 14.7 vs. 11.4 months; hazard ratio for death, 0.70; 95% confidence interval, 0.55 to 0.90; P = 0.004). Significant results were also seen with regard to progression-free survival (hazard ratio for disease progression or death, 0.74; 95% CI, 0.59 to 0.92) and confirmed objective response (in 44.3% of the patients in the trastuzumab deruxtecan group vs. 29.1% of those in the ramucirumab-paclitaxel group). The incidence of drug-related adverse events of any grade was 93.0% with trastuzumab deruxtecan and 91.4% with ramucirumab plus paclitaxel; the incidence of drug-related adverse events of grade 3 or higher was 50.0% and 54.1%, respectively. Adjudicated drug-related interstitial lung disease or pneumonitis occurred in 13.9% of the patients who received trastuzumab deruxtecan (grade 1 or 2 in 33 patients and grade 3 in 1) and in 1.3% of those who received ramucirumab plus paclitaxel (grade 3 in 2 patients and grade 5 in 1).</p><p><strong>Conclusions: </strong>Trastuzumab deruxtecan led to significantly longer overall survival than ramucirumab plus paclitaxel among patients with HER2-positive metastatic gastric cancer or gastroesophageal junction adenocarcinoma. Adverse events were common in both groups. Events of interstitial lung disease or pneumonitis with trastuzumab deruxtecan, a known risk, were mainly low-grade. (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Gastric04 ClinicalTrials.gov number, NCT04704934.).</p>","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":"336-348"},"PeriodicalIF":96.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144200803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Case of Crackles. 噼啪声的案例。
IF 96.2 1区 医学
New England Journal of Medicine Pub Date : 2025-07-24 DOI: 10.1056/NEJMimc2406689
Joanne I Hsu, Anand Vaidya, Jia Luo, Rebecca M Baron, Joel Katz
{"title":"A Case of Crackles.","authors":"Joanne I Hsu, Anand Vaidya, Jia Luo, Rebecca M Baron, Joel Katz","doi":"10.1056/NEJMimc2406689","DOIUrl":"https://doi.org/10.1056/NEJMimc2406689","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"393 4","pages":"e5"},"PeriodicalIF":96.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. Obinutuzumab治疗活动性狼疮性肾炎的疗效和安全性。
IF 96.2 1区 医学
New England Journal of Medicine Pub Date : 2025-07-24 DOI: 10.1056/NEJMc2506672
Andrea Angeletti, Maddalena Marasà, Paolo Cravedi
{"title":"Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.","authors":"Andrea Angeletti, Maddalena Marasà, Paolo Cravedi","doi":"10.1056/NEJMc2506672","DOIUrl":"https://doi.org/10.1056/NEJMc2506672","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"393 4","pages":"408"},"PeriodicalIF":96.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enteral Nutrition in Hospitalized Adults. Reply. 住院成人肠内营养。回复。
IF 96.2 1区 医学
New England Journal of Medicine Pub Date : 2025-07-24 DOI: 10.1056/NEJMc2506662
Leah Gramlich, Peggi Guenter
{"title":"Enteral Nutrition in Hospitalized Adults. Reply.","authors":"Leah Gramlich, Peggi Guenter","doi":"10.1056/NEJMc2506662","DOIUrl":"https://doi.org/10.1056/NEJMc2506662","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"393 4","pages":"416"},"PeriodicalIF":96.2,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信